HUE030794T2 - Dihidro-pirido-ftalazinon-származékok szintetizálási folyamatai - Google Patents

Dihidro-pirido-ftalazinon-származékok szintetizálási folyamatai Download PDF

Info

Publication number
HUE030794T2
HUE030794T2 HUE11740513A HUE11740513A HUE030794T2 HU E030794 T2 HUE030794 T2 HU E030794T2 HU E11740513 A HUE11740513 A HU E11740513A HU E11740513 A HUE11740513 A HU E11740513A HU E030794 T2 HUE030794 T2 HU E030794T2
Authority
HU
Hungary
Prior art keywords
fej
compound
formula
acid
methyl
Prior art date
Application number
HUE11740513A
Other languages
English (en)
Inventor
Bing Wang
Daniel Chu
Yongbo Liu
Quan Jiang
Lei Lu
Original Assignee
Medivation Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Technologies Inc filed Critical Medivation Technologies Inc
Publication of HUE030794T2 publication Critical patent/HUE030794T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Claims (6)

1. MédSSSî· 4 }'áy Mppgí Vágyáig
•IlllliiSi; Πλ vagy|ä égy aà|ï3 aldiiMalísk aMk s rnadsae? « kàvaPeadkbd; âi; ss 4;-óv lépjaiá átgyilglái:
(5), vagy emsak spy ·§ϋ# IddssPsasedpgisrsMal magákafái ahaä & pleads« SS-aikii ápol m: vlpös képkáP vegyviais! vagy asaak sgjél ágy ék&k silk aogy a iggss kègfetâ vagypaívt
|4 4 vsgy ásnák agy spÉ pgqkékiskP ê§ WW vágy ágy Lawís-sgy JsiegpiglPg fá^apggk, aköi R spárgása ϋΗ'8'aM. 2, .¾ 1 Jgésíyggní sagdpti: aiggsgag adói a ;adak;5i«asa; a) agy fgmsgaiogga^/sips aggg y aagîaa a fgnplpfegspg TiÇiS vagy SaQil vagy b) vsspöt. vagy al gpsogén agy ^aPáíasváías jafeaitálsaa, sági *oaU vsPkea a parkaplisafe a Kaassrao cvogaráP: váiassfptk palMam.. rákap ás piaiba; vagy <!} MCN8H3. ahol Ma kávét*«* osoppt váis«tett: y. Ns: Kés 8s4bi. , . ,,.Λ . S. Αχ s. tgènypb «eàbs rsábsssy sh«: a ssvvsy sav a köveiké csaíx<?tbói vasasa: HCi. Hör. mf;-h^y4·** H3P04. 4, mCagy sxsrm táv a kèvafcszâ csep&amp;ïlbêi viasza·; ^mmm», vajssv» febyor-s^isav, p-ioïvalsjoivsiisav es n^PPfcnsav: vagy b) aboi a Levis· sav a kévô^ad ceoponixs v^?«:íA{Ci3, .TíC;4 ^Ci4. sab ZnCiJ
5, Az 1 #aypoa; abci a i4m» taps» vegyül»** vagy *«Κ·«ά$$ % **>* m? â $*** *ô$^· végÿiMèb
(3K vggy m «W* m sav Kte&amp;ése» S-OH-vss üs5# ahol R a kavard csontból vágott, mű P; p(p ippropi butít âs isobutS; és s sav a kévePzO «soporSP vaitmbb: HD. atslsav. p4o:Psv:;Pe$av és eiaoH^taav, 4 Ár * > XX^ * s'e X * sto** *>? a 4 î* -¾. ^ ''Λ* <> '* *' açv a - s , ' » \- a - w κβριρ v«ovùS(?M:
(Í műmnek «l '«*» ui-1,2.4-^^*5-safb^^ <μ£*ι$*.
7. A δ. :çàfîypont szmtè m a ks^^as kosyiinény â ***·»»&amp; jafesb: agy fete? hasznába v^esukSi w Jpaièfâbea kóréibetüt 60 as 90 X *ëzm aho! a fete aao8 aPPt thiamin és a vbsaegkôiè mt · -jv· v< I: Métisse? &amp;ε i l H* sépleSs vepypj:
t(l)v ,5 (8}·§>% k*H&amp;*ïû
(8), V8g §gï«séiâr^¥.:feMSsi ħ«i|äu c; a 8, igényper $£Âi méáíef, aho= s ös^í> &amp;ït s; 3ïioî s (ényksHXÍOás ado* a*s3>s« a kávetkszö v<,op*;!0öi vaSasaot:: ^abCO'i K2C03 ô? C%2C08 vagy bï aiu2 a ián>!2ádd addteseihao N&amp;H vggy HH. 10. Ä? » i$H* «W®·** VÎW #«* ^ fc&amp;jak «t* kogv s (?}$$ tepielMßfefeft?
ÏÏh '.' '? ^-î-yi'ù! \ *:&amp;'">> ! \y^as A' ^ »-""-Λ ^aalù vagyáé' ^a*y ^ad, «1 fesgy a }>' - y6§ÿp#5k
i.>n va§ftm«Ée<?y soiâi egy sav *gag»juk} ^*i«»d&amp;«MÉp umé^^ed^ vài^Â^savgMfesciàfesv# HCl ¢3 pHoiuolsiriilfefisav.
18, Mtes? as (1}.¾¾ kâpietO v%§yi|ï«&amp;
ί'5 \ C'Uj vagy wak «gys-pfa slagiiaagfey Pel· s aiáassa a si: ai (Ca» kégieSü v%gy;.ás>sí:
(5), yggy ef;:*:?:·>·. agy spjéthrldîàïgÎfÎ-mèïf'îôhldrêlfsïî algáiknak. aks? R Jgkídksya 01·<:8ν#4 apai sz |Sj:% kàpMp vagygiglatvggy sgagk sóját ágy Pipák *21, Η<%$ g (iPgg Hapsi vggyigte
(9), vagy esnék agy sóját agy mag oCsgsapsn agy mdgkaiosaastei avsgánpuk kotgipeidi Q ég 148 ':C kpgsltí timêrsèkifePîé, kêpbgif Ces 4Bóía kökdít; ÄärPÄ körgadös; apP R Jéígalgae CiRCCgRil. 1|. Aa 12. ?g&amp;í:ypont avednk mods», aboi a fediRCPsaar al agy fègvbgdydrki. áf®s a#!fö§aSea alM^dPapd RaBH4 vagy CgCCBHS; vagy p vaspör; vagy a) T;CC vagy SnCC. vagy d) hidrogén agy pmppifé® aPgkeéRl gsaibaa ga ataienak %® a pvsiap cgaggr&amp;á! vliaacötk pliêfpp mkkekia piagaa.
14. Modakar ál (1)·'©8 képiatü ysayalèt:
íl% vagy ennek Sgÿ gps eltekátea. shoi antetersktePSÄtiP áll: M |§}PP képei vagyuiste
vágy snmp agy $δ§|1pagils§ak; ai5p R pfápáss Clpptei ansi as sptekêpei yágyníáleiyaiy anaat: aóját úgy pipák sis, Slgy a Π 0) -es képsi vëgpièM
{10 K vagy ennek s§y sept agy mdu kälteste teSPite· gap R ipsa psg Pi-PPapI. IP az tg, igéaypsnt ss&amp;Nati aPïisagk ahP g teakPStek al saspn vagy p agy fênviètend ; : ahi adat! eseten a SámPáPinl Ra8H4; y eg y p PÉôgèa sgy átmeneti te pieniéîéSem iÉai aded eseten aa âimsnsk îlrn a kôtekte eseggrte teasaipk tePÄRn Pkki ás pains,
11, Aa 14, igeeygeai saeriei m&amp;àœmÆ®-à (löte képiéi vegyteist vagy snnsk spàî lay álljak sip aogy a pyes képei yegyiaiât "î:· k -y- y" (/> f- p ;k J§ I I I 11 * 1 1 *: 1 8 I fr- S' S: -SS: ψ % f Ï ï S- I: I 1 I * f i 1¾. * ff if 3 O rn S S ç
".V; S IS ë> SI- i? 8 s if
·;; 8 s S o s· S ,¾
i f f « i : I 111
&amp; B 8 I :~r % to I c: « s S ff Ψ w S si i f- i £ ti Ilit f s fii i ' f t i f f % 1 f 1111 I I f t I Í f f I § ë &amp; ky Ψ "X sr. S· ··.» O g &amp; ,,... a t » II i : r f f f :k. m ív- %L· Ä I i i: t S t i i· i I I il: Q g· g: If *ξ y SV » 0 B if' I If " i 8 ivr» w ?>> <<\f s**' if; i 1111 ? ! .Ç cy· ΐΰ· ^ ^ ® i if 1 8 ! I 8 § :f III f I R S I I I f s I i p ï e I S T f: g 8 self
(ό;ύ »aj* «MMi «w sasi a***·» MMtHmààmm&amp;Çk. m r i ******c !'c'5'Ää S A 18 «w* «MT. s»i * '« ««. «*> «rnt «swa*» « ä,!"·*Ä ·“» **» felbontást végïwnk «
(5). *. a ?ö, wnon mom^r. *»*§» iMst^ al isolt çÿelbeo o nasser tartalmasa mèc agy kiáss m tos marnám <s. anoi a kiraás ásó **"> '-Η · '"'" ’ 'Kw ockfep fitiol nácit cwíhcn a GH;RAoKAK$je$<ooís K/ vs§y AV >·*&amp;* ( ^. .f ^.,.. ,;.T. fej a*« «w» a «wm* ax««» m* *» ™»9· «Λ * *·* a 22 a is fénypont sssrisá mécséé; snoi a ünss ?$inoo|ást egy ^,muî^:î mcágmsteges Kfomatcgtá»^ v Bed chtmm^y " * «Ο*·* * m,QHmiPMë ^ mmmrn zmx&amp;Wémmm g§r« állófej m * «W '; ' öíSíXH) adói Sdíit eembí-o a CHlRAtPAKi o«fop IC ötffcp. vagy M ** ««s» » m*m art««» 'SS <w mcass (Sá mw** ****** «»»»»* 2' :,;;-,:Á::: sfeie’f : <0 aíÍ’A:' :' AXAi'': -fe:A';:;:·’
m , λ · tQ
shö! ^jsfentèsfc Cl'CS-sM
HUE11740513A 2010-02-08 2011-02-08 Dihidro-pirido-ftalazinon-származékok szintetizálási folyamatai HUE030794T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30245710P 2010-02-08 2010-02-08

Publications (1)

Publication Number Publication Date
HUE030794T2 true HUE030794T2 (hu) 2017-06-28

Family

ID=44354222

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11740513A HUE030794T2 (hu) 2010-02-08 2011-02-08 Dihidro-pirido-ftalazinon-származékok szintetizálási folyamatai

Country Status (21)

Country Link
US (2) US8765945B2 (hu)
EP (1) EP2533640B1 (hu)
JP (1) JP5735988B2 (hu)
KR (1) KR101826652B1 (hu)
CN (1) CN102834008B (hu)
AU (1) AU2011213584B2 (hu)
BR (1) BR112012019648B1 (hu)
CA (1) CA2788114C (hu)
CY (1) CY1118575T1 (hu)
DK (1) DK2533640T3 (hu)
ES (1) ES2606174T3 (hu)
HU (1) HUE030794T2 (hu)
IL (1) IL221170A (hu)
MX (1) MX340319B (hu)
PL (1) PL2533640T3 (hu)
PT (1) PT2533640T (hu)
RU (1) RU2561732C2 (hu)
SG (1) SG182784A1 (hu)
SI (1) SI2533640T1 (hu)
WO (1) WO2011097602A1 (hu)
ZA (1) ZA201205538B (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2466565T3 (es) 2008-08-06 2014-06-10 Biomarin Pharmaceutical Inc. Inhibidores dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP)
CA2787844C (en) 2010-02-03 2019-08-27 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
AU2011213584B2 (en) 2010-02-08 2016-05-12 Medivation Technologies Llc Processes of synthesizing dihydropyridophthalazinone derivatives
SI2630146T1 (sl) 2010-10-21 2020-12-31 Medivation Technologies Llc Kristalinična tosilatna sol (8S,9R)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1H-1,2,4-triazol-5-IL)- 8,9-dihidro-2H-pirido(4,3,2-DE)ftalazin-3(7H)-ON
JP2016529284A (ja) 2013-08-27 2016-09-23 ノースイースタン ユニバーシティ ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法
TW201605814A (zh) 2013-11-07 2016-02-16 拜奧馬林製藥公司 用於合成經保護之ｎ－烷基三唑甲醛的三唑中間體
WO2016019125A1 (en) * 2014-07-31 2016-02-04 Biomarin Pharmaceutical Inc. Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them
CN104557917A (zh) * 2014-12-12 2015-04-29 重庆博腾制药科技股份有限公司 一种5-卤代氮杂环吲哚的制备方法
US20180155311A1 (en) * 2015-05-26 2018-06-07 Dsm Ip Assets B.V. Separation of chiral isomers by sfc
US9708319B1 (en) * 2016-06-13 2017-07-18 Yong Xu Synthesis of PARP inhibitor talazoparib
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2019075032A1 (en) 2017-10-13 2019-04-18 Merck Patent Gmbh COMBINATION OF A PARP INHIBITOR AND A PD-1 AXIS BINDING ANTAGONIST
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
US20210355223A1 (en) 2018-11-05 2021-11-18 Pfizer Inc. Combinations for Treating Cancer
US20240209061A1 (en) 2020-03-09 2024-06-27 Pfizer Inc. Fusion proteins and uses thereof
EP4243785A1 (en) 2020-11-13 2023-09-20 Pfizer Inc. Talazoparib soft gelatin capsule dosage form
CN116802321A (zh) 2020-12-07 2023-09-22 辉瑞公司 鉴定对他拉唑帕尼治疗敏感的肿瘤的方法以及其治疗方法
WO2022200982A1 (en) 2021-03-24 2022-09-29 Pfizer Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
WO2023131894A1 (en) 2022-01-08 2023-07-13 Pfizer Inc. Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof
WO2024074959A1 (en) 2022-10-02 2024-04-11 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2024127140A1 (en) 2022-12-17 2024-06-20 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415504A (en) 1981-09-21 1983-11-15 Tanabe Seiyaku Co., Ltd. p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine
JPS58225065A (ja) 1982-06-21 1983-12-27 Nippon Shinyaku Co Ltd ２−キノロン誘導体
US5328905A (en) 1987-07-20 1994-07-12 Duphar International Research B.V. 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
ID19155A (id) 1996-12-13 1998-06-18 Tanabe Seiyaku Co Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya
DE19727410A1 (de) 1997-06-27 1999-01-07 Hoechst Schering Agrevo Gmbh 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
TW430656B (en) 1997-12-03 2001-04-21 Dainippon Ink & Chemicals Quinolinone derivative, method for preparing the same, and anti-allergic agent
AU9298798A (en) 1998-05-15 1999-12-06 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
JP2001302669A (ja) 2000-04-18 2001-10-31 Meiji Seika Kaisha Ltd 三環性フタラジノン誘導体
JP2002284699A (ja) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
CA2476406A1 (en) 2002-02-19 2003-08-28 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
EP1340819A1 (en) 2002-02-28 2003-09-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Microsatellite markers
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
EP1400244A1 (en) 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
WO2004043959A1 (ja) 2002-11-12 2004-05-27 Mochida Pharmaceutical Co., Ltd. 新規parp阻害剤
MXPA05009661A (es) * 2003-03-12 2006-03-08 Kudos Pharm Ltd Derivados de ftalazinona.
MXPA05012812A (es) * 2003-05-28 2006-02-28 Guilford Pharm Inc Compuestos, metodos y composiciones farmaceuticas para inhibir poli(adenosina-5'-difosfo-ribosa)polimerasa(parp).
US7269138B2 (en) * 2003-06-04 2007-09-11 Motorola, Inc. Distributed MAC protocol facilitating collaborative ranging in communications networks
UA85576C2 (ru) 2004-02-18 2009-02-10 Астразенека Аб Тетразольные соединения и их применение в качестве метаботропических антагонистов рецепторов глутамата
GB0612971D0 (en) 2006-06-30 2006-08-09 Angeletti P Ist Richerche Bio Therapeutic compounds
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
WO2008135826A2 (en) 2007-05-03 2008-11-13 Pfizer Limited 2 -pyridine carboxamide derivatives as sodium channel modulators
EP2178875A1 (en) 2007-08-22 2010-04-28 4Sc Ag Indolopyridines as inhibitors of the kinesin spindle protein (eg5 )
WO2009046205A1 (en) * 2007-10-03 2009-04-09 Eisai Research Institute Parp inhibitor compounds, compositions and methods of use
JP2011511078A (ja) 2008-02-06 2011-04-07 レアド トヘラペウトイクス，インコーポレーテッド ポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）のベンズオキサゾールカルボキサミド阻害剤
ES2466565T3 (es) 2008-08-06 2014-06-10 Biomarin Pharmaceutical Inc. Inhibidores dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP)
CA2735560A1 (en) 2008-08-12 2010-02-18 Boehringer Ingelheim International Gmbh Process for preparing cycloalkyl-substituted piperazine compounds
CA2787844C (en) 2010-02-03 2019-08-27 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
US20110190266A1 (en) 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
AU2011213584B2 (en) 2010-02-08 2016-05-12 Medivation Technologies Llc Processes of synthesizing dihydropyridophthalazinone derivatives
WO2011130661A1 (en) 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
WO2011140009A1 (en) 2010-05-04 2011-11-10 Biomarin Pharmaceutical Inc. Methods of using semi-synthetic glycopeptides as antibacterial agents
SI2630146T1 (sl) 2010-10-21 2020-12-31 Medivation Technologies Llc Kristalinična tosilatna sol (8S,9R)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1H-1,2,4-triazol-5-IL)- 8,9-dihidro-2H-pirido(4,3,2-DE)ftalazin-3(7H)-ON
WO2012166151A1 (en) 2011-06-03 2012-12-06 Biomarin Pharmaceutical Inc. Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
WO2013028495A1 (en) 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
US20130053365A1 (en) 2011-08-30 2013-02-28 Biomarin Pharmaceutical, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
TW201605814A (zh) 2013-11-07 2016-02-16 拜奧馬林製藥公司 用於合成經保護之ｎ－烷基三唑甲醛的三唑中間體
WO2016019125A1 (en) 2014-07-31 2016-02-04 Biomarin Pharmaceutical Inc. Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them

Also Published As

Publication number Publication date
KR20120125630A (ko) 2012-11-16
MX2012008903A (es) 2012-08-17
PT2533640T (pt) 2017-01-03
DK2533640T3 (en) 2017-01-23
WO2011097602A1 (en) 2011-08-11
BR112012019648A2 (pt) 2016-08-09
CY1118575T1 (el) 2017-07-12
EP2533640A4 (en) 2013-07-10
EP2533640A1 (en) 2012-12-19
JP2013518910A (ja) 2013-05-23
EP2533640B1 (en) 2016-09-28
IL221170A0 (en) 2012-09-24
SG182784A1 (en) 2012-09-27
ZA201205538B (en) 2013-09-25
KR101826652B1 (ko) 2018-02-07
RU2012138345A (ru) 2014-03-20
SI2533640T1 (sl) 2017-02-28
AU2011213584A1 (en) 2012-08-16
JP5735988B2 (ja) 2015-06-17
MX340319B (es) 2016-07-06
IL221170A (en) 2015-05-31
US9926303B2 (en) 2018-03-27
RU2561732C2 (ru) 2015-09-10
CN102834008A (zh) 2012-12-19
AU2011213584B2 (en) 2016-05-12
CN102834008B (zh) 2014-04-23
CA2788114C (en) 2018-11-06
ES2606174T3 (es) 2017-03-23
BR112012019648B1 (pt) 2022-04-19
US20140323725A1 (en) 2014-10-30
US20110196153A1 (en) 2011-08-11
CA2788114A1 (en) 2011-08-11
US8765945B2 (en) 2014-07-01
PL2533640T3 (pl) 2017-06-30

Similar Documents

Publication Publication Date Title
HUE030794T2 (hu) Dihidro-pirido-ftalazinon-származékok szintetizálási folyamatai
US20050197364A1 (en) Amide compounds as ion channel ligands and uses thereof
CA2758289A1 (en) Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands
FR2786185A1 (fr) 3-aminomethylpyrrolidines, compositions pharmaceutiques les contenant et procedes pour les preparer
CA2880299A1 (en) Process for the synthesis of substituted urea compounds
JP2013517267A (ja) テトラゾールメタンスルホン酸塩の製造方法及びそれに用いられる新規化合物
HUE030696T2 (hu) Eljárás dabigatran etexilát és intermedierjei elõállítására
JP2018516912A (ja) アプレミラストおよびその新規な多形の改善された製造方法
TW200800895A (en) Novel compounds
CN101747292B (zh) 苯甲酰胍-曲美他嗪的偶联物、其制备方法及其医药用途
CN106674097A (zh) 一种瑞戈非尼杂质的制备方法
WO2020171073A1 (ja) ベンゾアゼピン誘導体の製造方法及びその中間体
JP7182562B2 (ja) ２－（［１，２，３］トリアゾール－２－イル）－安息香酸誘導体の製造
NL2000532C2 (nl) Chromaanderivaten.
EP2531499B1 (en) Process for preparing voriconazole by using new intermediates
WO2018143165A1 (ja) 光学活性ピロリジン化合物の製造方法
CN105272921A (zh) 一种制备Ceritinib的方法及其中间体化合物
JP2006519806A (ja) 尿素誘導体および疼痛治療におけるバニロイド受容体拮抗剤としてのそれらの使用。
US20080242866A1 (en) Synthesis of anthranilamides
CN103319470B (zh) 基于Sant‑75结构的化合物
CN104744424B (zh) 一种替卡格雷中间体的制备方法
CN101830848B (zh) 一种多胺衍生物及其制备方法和应用
CN116217457A (zh) 一种4-氨基-1h-吡咯化合物、制备方法和用途
CN116082259A (zh) 氨基甲酸酯基或氨甲酰基取代的5-ht2b拮抗剂
Tekluu et al. Synthesis and Biological Evaluation of 1H-(Indole-5-yl)-3-Substituted-1, 2, 4-Oxadiazoles as Novel 5-Lox Inhibitors